Cat­a­lyst Phar­ma­ceu­ti­cals to ac­quire com­mer­cial rights to an Ei­sai seizure med­ica­tion for $160M

Cat­a­lyst Phar­ma­ceu­ti­cals is adding an­oth­er drug to its ar­se­nal by pick­ing up a drug from Ei­sai.

The Flori­da-based rare dis­ease biotech an­nounced on Mon­day that it has en­tered in­to an agree­ment with the Japan­ese phar­ma Ei­sai to ac­quire the US rights to the seizure treat­ment Fy­compa, along with an ex­clu­sive op­tion pe­ri­od to re­view, eval­u­ate and pos­si­bly ne­go­ti­ate an ac­qui­si­tion of a rare epilep­sy as­set in Ei­sai’s pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER